We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Encysive’s blood clot prevention drug Argatroban, approved to prevent blood clots in heart attack victims, may also help open blocked arteries in stroke patients, according to a study published in the Aug. 14 issue of Archives of Neurology.
Global pharmaceutical drug sales have remained steady over the past several months, averaging 5 percent growth, healthcare consultant IMS Health reported.
By 2010, generics will dominate the schizophrenia drug market, and Pfizer will be the only major drug firm to maintain a strong position after its current leading antipsychotic goes generic, according to an Aug. 11 report by research firm Datamonitor.
The growing number of states regulating industry gifts to healthcare professionals will spell trouble for companies trying to comply with a growing number of inconsistent state requirements, experts say.
Apotex’s decision to launch its generic version of the blockbuster blood thinner Plavix long before a court decides if it has a valid patent challenge may not be as risky as it first seemed, according to newly released details of its settlement agreement with sanofi-aventis and Bristol-Myers Squibb (BMS).
After almost seven months of searching for a buyer, drug company ImClone Aug. 10 announced it is no longer for sale because takeover offers were too low.
The trend toward more state regulation of industry gifts to healthcare professionals will spell trouble for companies trying to comply with a growing number of inconsistent state requirements, experts say.
Apotex has launched its generic version of Plavix, bringing an end to a patent settlement agreement with sanofi-aventis and Bristol-Myers Squibb (BMS) and possibly forcing an earlier-than-expected court date on the patent challenge.